Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

William J. Gradishar, MD
Published: Tuesday, Oct 17, 2017



William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Trastuzumab (Herceptin) is used in different settings in the treatment of patients with HER2-positive breast cancer.

There is a trend forming, says Gradishar, as dual HER2-targeting is being used first in the preoperative, postoperative, and early in the sequence for patients with metastatic disease.
 


William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Trastuzumab (Herceptin) is used in different settings in the treatment of patients with HER2-positive breast cancer.

There is a trend forming, says Gradishar, as dual HER2-targeting is being used first in the preoperative, postoperative, and early in the sequence for patients with metastatic disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x